J. Corral

4.9k total citations · 4 hit papers
60 papers, 3.5k citations indexed

About

J. Corral is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, J. Corral has authored 60 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 39 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in J. Corral's work include Lung Cancer Treatments and Mutations (32 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Lung Cancer Research Studies (14 papers). J. Corral is often cited by papers focused on Lung Cancer Treatments and Mutations (32 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Lung Cancer Research Studies (14 papers). J. Corral collaborates with scholars based in Spain, United States and Italy. J. Corral's co-authors include Tony Mok, Yi‐Long Wu, Kazuhiko Nakagawa, Rafael Rosell, Luis Paz‐Ares, Adam Płużański, Maria Rita Migliorino, Ki Hyeong Lee, Xiangdong Zhou and Seiji Niho and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

J. Corral

58 papers receiving 3.4k citations

Hit Papers

Dacomitinib versus gefitinib as first-line treatment for... 2012 2026 2016 2021 2017 2012 2013 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
    2017 854 citations Yi‐Long Wu, Ying Cheng et al. The Lancet Oncology profile →
  2. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
    2012 447 citations Luis Paz‐Ares, Filippo de Marinis et al. The Lancet Oncology profile →
  3. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
    2013 438 citations Luis Paz‐Ares, Filippo de Marinis et al. Journal of Clinical Oncology profile →
  4. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
    2018 331 citations Tony Mok, Ying Cheng et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Corral Spain 26 2.5k 2.3k 856 457 222 60 3.5k
Panos Fidias United States 25 1.8k 0.7× 1.7k 0.7× 925 1.1× 276 0.6× 210 0.9× 58 3.0k
Janessa Laskin Canada 30 2.1k 0.8× 2.2k 1.0× 1.0k 1.2× 774 1.7× 299 1.3× 187 3.8k
Michael S. Rabin United States 27 2.3k 0.9× 1.9k 0.8× 654 0.8× 419 0.9× 257 1.2× 86 3.2k
Michele Aieta Italy 24 997 0.4× 1.2k 0.5× 638 0.7× 600 1.3× 315 1.4× 116 2.3k
Toshinari Yamashita Japan 24 1.6k 0.6× 1.9k 0.9× 1.3k 1.5× 1.1k 2.5× 195 0.9× 135 3.7k
Jeanny B. Aragon‐Ching United States 27 1.2k 0.5× 1.4k 0.6× 692 0.8× 455 1.0× 600 2.7× 141 2.9k
Alexis B. Cortot France 28 2.7k 1.1× 2.2k 1.0× 1.4k 1.6× 609 1.3× 212 1.0× 185 3.8k
Laurent Greillier France 28 1.8k 0.7× 1.6k 0.7× 530 0.6× 238 0.5× 151 0.7× 206 3.0k
Mohit Butaney United States 19 1.8k 0.7× 1.5k 0.6× 892 1.0× 894 2.0× 201 0.9× 68 2.7k
Herbert H. Loong Hong Kong 30 1.3k 0.5× 1.5k 0.7× 790 0.9× 548 1.2× 412 1.9× 163 3.0k

Countries citing papers authored by J. Corral

Since Specialization
Citations

This map shows the geographic impact of J. Corral's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Corral with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Corral more than expected).

Fields of papers citing papers by J. Corral

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Corral. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Corral. The network helps show where J. Corral may publish in the future.

Co-authorship network of co-authors of J. Corral

This figure shows the co-authorship network connecting the top 25 collaborators of J. Corral. A scholar is included among the top collaborators of J. Corral based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Corral. J. Corral is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pu, Xingxiang, Juan Li, Bo Zhang, et al.. (2024). Efficacy in patients with EGFR -positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050. Future Oncology. 20(37). 2971–2982. 2 indexed citations
2.
Reck, Martin, Sanjay Popat, Christian Grohé, et al.. (2023). Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. Lung Cancer. 179. 107173–107173. 14 indexed citations
3.
Mezquita, Laura, J. Corral, Manuel Cobo, et al.. (2023). The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium. Clinical & Translational Oncology. 26(2). 352–362. 1 indexed citations
4.
5.
Mok, Tony, Ying Cheng, Xiangdong Zhou, et al.. (2018). Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations. Journal of Clinical Oncology. 36(22). 2244–2250. 331 indexed citations breakdown →
6.
Garassino, Marina Chiara, Byoung Chul Cho, Julien Mazières, et al.. (2018). P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC. Journal of Thoracic Oncology. 13(10). S467–S468. 1 indexed citations
7.
Mok, Tony, Kazuhiko Nakagawa, Rafael Rosell, et al.. (2018). MA26.11 Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC. Journal of Thoracic Oncology. 13(10). S454–S454. 5 indexed citations
8.
Banerjee, Susana, Raffaele Califano, J. Corral, et al.. (2017). Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey. Annals of Oncology. 28(7). 1590–1596. 92 indexed citations
9.
10.
Falcón, Alejandro, et al.. (2017). P3.02c-034 A Single Institution Experience with Immunotherapy as an Effective Therapy Approach of Advance Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1293–S1294. 1 indexed citations
11.
Wu, Yi‐Long, Ying Cheng, Xiangdong Zhou, et al.. (2017). Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet Oncology. 18(11). 1454–1466. 854 indexed citations breakdown →
12.
13.
Socinski, Mark A., Frederic J. Kaye, David R. Spigel, et al.. (2016). Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. Clinical Lung Cancer. 18(1). 68–76.e2. 67 indexed citations
14.
Martín, Miguel, Manuel Ruíz‐Borrego, José M. Pérez, et al.. (2016). A phase I study of sonidegib (S) in combination with docetaxel (D) in patients (pts) with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study). Annals of Oncology. 27. vi87–vi87. 3 indexed citations
15.
Pastor, María Dolores, Ana Nogal, Sonia Molina‐Pinelo, et al.. (2016). IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF). Journal of Thoracic Oncology. 11(12). 2183–2192. 19 indexed citations
16.
Remón, Jordi, et al.. (2014). Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies. Cancer Treatment Reviews. 41(1). 27–34. 54 indexed citations
17.
Paz‐Ares, Luis, Filippo de Marinis, Mircea Dediu, et al.. (2013). PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 31(23). 2895–2902. 438 indexed citations breakdown →
18.
Capdevila, Jaume, L. Iglesias, Irene Halperín, et al.. (2012). Sorafenib in metastatic thyroid cancer. Endocrine Related Cancer. 19(2). 209–216. 92 indexed citations
19.
Paz‐Ares, Luis, Filippo de Marinis, Mircea Dediu, et al.. (2012). Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. The Lancet Oncology. 13(3). 247–255. 447 indexed citations breakdown →
20.
Gridelli, Cesare, Filippo de Marinis, Jean-Louis Pujol, et al.. (2012). Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 7(11). 1713–1721. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Panos Fidias Breakdown of academic impact, for papers by Janessa Laskin Breakdown of academic impact, for papers by Michael S. Rabin Breakdown of academic impact, for papers by Michele Aieta Breakdown of academic impact, for papers by Toshinari Yamashita Breakdown of academic impact, for papers by Jeanny B. Aragon‐Ching Breakdown of academic impact, for papers by Alexis B. Cortot Breakdown of academic impact, for papers by Laurent Greillier Breakdown of academic impact, for papers by Mohit Butaney Breakdown of academic impact, for papers by Herbert H. Loong
Rankless by CCL
2026